Views 652
Citations 0
Comment & Response
March 10, 2015

Preventing Prescription Opioid Abuse—Reply

Author Affiliations
  • 1Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland
  • 2Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(10):1060-1061. doi:10.1001/jama.2015.0524

In Reply We agree with Drs Ballantyne and Kolodny that opioid analgesics are not the most effective treatment option for certain types of chronic pain. This recognition, combined with the public health risks associated with opioid analgesics, prompted revisions to the indications for ER/LA opioid analgesics in 2013.

Manufacturers must now instruct prescribers to “reserve [ER/LA opioid analgesics] for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.”1 In addition, in recent years, the FDA has approved several nonopioid medications to treat some of the most common chronic pain conditions.

First Page Preview View Large
First page PDF preview
First page PDF preview